Richard Pacca, MD
Cardiovascular Disease · Oxford, NCNPI 1619189057
Payments from drug & device makers
Across 202 payments — averaging $16.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$507
- Biotronik Inc.$382
- Boston Scientific$337
- AstraZeneca$300
- Novartis$266
- Johnson & Johnson$224
- plus $1K from 23 others
What the payments were for
- Food & beverage$3,37299%
- Education$511%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 9 | $507 |
| Biotronik Inc. | 17 | $382 |
| Boston Scientific | 18 | $337 |
| AstraZeneca | 21 | $300 |
| Novartis | 19 | $266 |
| Johnson & Johnson | 19 | $224 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $174 |
| E.r. Squibb & Sons, L.L.C. | 8 | $140 |
| Regeneron Healthcare Solutions, Inc. | 9 | $137 |
| Lundbeck LLC | 7 | $117 |
| Amgen | 8 | $117 |
| Amarin Pharma, Inc. | 8 | $111 |
| Pfizer | 6 | $87 |
| Boehringer Ingelheim | 5 | $82 |
| Irhythm Technologies, Inc. | 5 | $78 |
| GSK | 6 | $74 |
| Sanofi-aventis U.S. LLC | 4 | $57 |
| Esperion Therapeutics, Inc. | 3 | $43 |
| Novo Nordisk | 2 | $39 |
| Merck | 1 | $22 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Bristol Myers Squibb | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Sensible Medical Innovations Inc | 1 | $14 |
| Mylan Specialty L.p. | 1 | $14 |
| Vifor Pharma, Inc. | 1 | $12 |
| Edwards Lifesciences | 1 | $11 |
| Medtronic | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,423 in reported general payments places this provider in the 55th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,580 | $1,181,530 |
| EntrestoSacubitril/Valsartan | 370 | $308,993 |
| XareltoRivaroxaban | 363 | $299,447 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 299 | $236,336 |
| FarxigaDapagliflozin Propanediol | 312 | $220,038 |
| JardianceEmpagliflozin | 160 | $138,542 |
| VascepaIcosapent Ethyl | 247 | $104,891 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 90 | $57,998 |
| Repatha SureclickEvolocumab | 77 | $56,377 |
| Breo ElliptaFluticasone/Vilanterol | 68 | $39,603 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 69 | $36,131 |
| Metoprolol Succinate | 2,890 | $33,505 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 51 | $32,401 |
| BrilintaTicagrelor | 32 | $27,604 |
| Icosapent Ethyl | 84 | $23,054 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $87 | $1,181,5301,580 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort | $300 | $312,463449 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $74 | $312,070436 claims |
| NovartisEntresto | $266 | $308,993370 claims |
| Johnson & JohnsonXarelto | $224 | $299,447363 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $82 | $177,666223 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $43 | $31,40158 claims |
| Sanofi-aventis U.S. LLCMultaq | $57 | $18,87512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 727 cardiovascular disease providers in North Carolina.
Other cardiovascular disease in Oxford
- John AlexanderDurham$76.8M
- Christopher GrangerDurham$24.7M
- Jonathan PicciniDurham$14.3M
- Adrian HernandezDurham$13.2M
- Gary FelkerDurham$12.7M
- Robert MentzDurham$6M
- Michael ShapiroWinston-Salem$5.4M
- Kirkwood AdamsChapel Hill$4.9M
- Matthew JanikWilmington$4M
- Nishant ShahDurham$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.